NCT05976204View on ClinicalTrials.gov

Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome

CompletedOBSERVATIONAL
Enrollment

501

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Congenital Heart DiseaseTetralogy of FallotNeutrophil-lymphocyte RatioAbsolute Lymphocyte CountThrombocyte-lymphocyte RatioOutcomeTOF
Interventions
PROCEDURE

ToF primary repair

ToF primary repair for patients with ToF

Trial Locations (1)

Unknown

National Cardiovascular Center Harapan Kita Jakarta Indonesia, Jakarta

All Listed Sponsors
lead

National Cardiovascular Center Harapan Kita Hospital Indonesia

OTHER

NCT05976204 - Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome | Biotech Hunter | Biotech Hunter